GSK (NYSE:GSK) announced today that the plaintiff in the next scheduled Zantac (ranitidine) litigation case, Kasza, voluntarily dismissed the case, which was set to proceed in the Illinois state court on June 10, 2024.

The company clarified that it did not settle the claim or pay for the dismissal.

Reiterating its stance on the safety of ranitidine, GSK highlighted the results from 16 epidemiological studies, which found "no consistent or reliable evidence" that ranitidine increases cancer risk.

Furthermore, the company reiterated its commitment to vigorously defend itself and manage this litigation in the best interests of the company and shareholders.